Author:
He Linling,Chaudhary Anshul,Lin Xiaohe,Sou Cindy,Alkutkar Tanwee,Kumar Sonu,Ngo Timothy,Kosviner Ezra,Ozorowski Gabriel,Stanfield Robyn L.,Ward Andrew B.,Wilson Ian A.,Zhu Jiang
Abstract
AbstractEbola virus (EBOV) glycoprotein (GP) can be recognized by neutralizing antibodies (NAbs) and is the main target for vaccine design. Here, we first investigate the contribution of the stalk and heptad repeat 1-C (HR1C) regions to GP metastability. Specific stalk and HR1C modifications in a mucin-deleted form (GPΔmuc) increase trimer yield, whereas alterations of HR1C exert a more complex effect on thermostability. Crystal structures are determined to validate two rationally designed GPΔmuc trimers in their unliganded state. We then display a modified GPΔmuc trimer on reengineered nanoparticles that encapsulate a layer of locking domains (LD) and a cluster of helper T-cell epitopes. In mice and rabbits, GP trimers and nanoparticles elicit cross-ebolavirus NAbs, as well as non-NAbs that enhance pseudovirus infection. Repertoire sequencing reveals quantitative profiles of vaccine-induced B-cell responses. This study demonstrates a promising vaccine strategy for filoviruses, such as EBOV, based on GP stabilization and nanoparticle display.
Publisher
Cold Spring Harbor Laboratory
Reference109 articles.
1. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA
2. Pathogenesis of the Viral Hemorrhagic Fevers
3. Ebola virus disease
4. Ebola outbreak 2014-2016 (https://www.who.int/csr/disease/ebola/en/).
5. Ebola situation reports: Democratic Republic of the Congo (https://www.who.int/ebola/situation-reports/drc-2018/en/).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献